We are a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology. Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. Currently, we have two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
The backbone of our approach is our proprietary Artificial Immune Modulation, or AIMTM, nanoparticle technology platform. The AIM technology enables us to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. Like natural dendritic cells, the AIM nanoparticles employ natural signaling proteins to deliver specific instructions to specific T cells directing a desired immune response.
(Note: NexImmune priced its upsized IPO on Feb. 11, 2021, by selling 6.47 million shares, up from 5.88 million, at $17, the top of the range, to raise $109.99 million. The deal’s size was increased by 16.9 percent at pricing. The company had just upsized its IPO in an S-1/A filing on Feb. 11 to 5.88 million shares, up from 4.69 million initially, and kept the price range at $15 to $17.)
|Address||9119 Gaither Road Gaithersburg, MD 20877|
|Phone Number||(301) 825-9810|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-26.9 mil (last 12 months)|
|Price range||$17.00 - $17.00|
|Est. $ Volume||$110.0 mil|
|Manager / Joint Managers||Barclays/ Cantor Fitzgerald/ Raymond James/ Allen & Co.|
|Expected To Trade:||2/12/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|